

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
*(Incorporated in Israel with limited liability)*  
**(Stock Code: 1696)**

**VOLUNTARY ANNOUNCEMENT**

This announcement is made by Sisram Medical Ltd (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that botulinum toxin type A for injection (DaxibotulinumtoxinA-lanm, with the trademark of 达希斐® in Mainland China and the English trademark of DAXXIFY®, project code RT002, the “**DAXXIFY®**”), a product sublicensed by Shanghai Fosun Pharmaceutical Industrial Development Company Limited\* (上海復星醫藥產業發展有限公司) (“**Fosun Pharmaceutical Industrial**”) which is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients, received the approval for drug registration from the National Medical Products Administration. As at the date of this announcement, apart from DAXXIFY®, there was no other DaxibotulinumtoxinA-lanm product approved in Mainland China.

The Company’s wholly-owned subsidiary was granted by Fosun Pharmaceutical Industrial in December 2022 the sublicense rights to use, import, sell and other commercialization (excluding manufacturing) of the DAXXIFY® in the region (i.e. Mainland China, Hong Kong and Macau Special Administrative Region, hereinafter the same) and the fields (i.e. the aesthetic indications, such as the improvement of moderate to severe glabellar lines in adult patients). The original licensor, Revance Therapeutics, Inc. which is based in the U.S., remains the right holder of the DAXXIFY® in the region.

The Company believes that upon the registration approval, the DAXXIFY® will become the Company’s first injectable product to be launched in Mainland China. As the core product in the injectable product matrix, DAXXIFY® will continue to play a cornerstone role in the development of the business and further strengthen the Company’s product portfolio and differentiated competitive advantages in China. It will continue to contribute new sources of revenue and consolidate the Company’s leadership in the global aesthetic market.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board  
**Sisram Medical Ltd**  
復銳醫療科技有限公司\*  
**Yi LIU**  
*Chairman*

Hong Kong, September 9, 2024

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as Executive Directors; Mr. Yifang WU and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.*

\* *for identification purpose only*